Abstract
With age, acquired mutations can cause clonal expansion of hematopoietic stem cells (HSC). This clonal hematopoiesis of indeterminate potential (CHIP) leads to an increased predisposition to numerous diseases including blood cancer and cardiovascular disease. Here, we report multi- ancestry genome-wide association meta-analyses of CHIP among 323,112 individuals (19.5% non-European; 5.3% have CHIP). We identify 15 genome-wide significant regions and nominate additional loci through multi-trait analyses, and highlight variants in genes involved in self- renewal and proliferation of HSC, telomere maintenance, and DNA damage response pathways. We then use Mendelian randomization to establish a causal relationship between CHIP and coronary artery disease. Next, we systematically profile consequences of CHIP across the phenome, which revealed strong associations with hematopoietic, neoplastic, and circulatory conditions corroborated by polygenic enrichment of CHIP loci in immune cells and cardiomyocytes. These findings expand the genomic and phenomic landscape of CHIP.
Competing Interest Statement
All unrelated to the present work: A.G.B. is a scientific co-founder and has equity in TenSixteen Bio. B.L.E. has received research funding from Celgene, Deerfield, Novartis, and Calico and consulting fees from GRAIL. B.L.E is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, TenSixteen Bio, Skyhawk Therapeutics, and Exo Therapeutics. M.C.H. has received consulting fees from CRISPR Therapeutics and is on the medical advisory board of Miga Health. P.N. reports grant support from Amgen, Apple, AstraZeneca, Novartis, and Boston Scientific, consulting income from Apple, AstraZeneca, Blackstone Life Sciences, Genentech, and Novartis, and spousal employment at Vertex, all unrelated to the present work. P.N., A.G.B, S.J., and B.E. are scientific advisors with equity in TenSixteen Bio, which had no role in the present work. P.T.E. receives sponsored research support from Bayer AG and IBM Research; he has also served on advisory boards or consulted for Bayer AG, MyoKardia, and Novartis. S.J. is a consultant to Novartis, Roche Genentech, AVRO Bio, and Foresite Labs, and on the scientific advisory board for Bitterroot Bio, founder and equity holder of TenSixteen Bio. V.G.S. serves as an advisor to and/or has equity in Branch Biosciences, Ensoma, Novartis, Forma, Sana Biotechnology, and Cellarity. All other authors declare that they have no competing interests.
Funding Statement
Z.Y. is supported by a grant from NHLBI (5T32HL007604-37). A.G.B. is supported by a Burroughs Wellcome Foundation Career Award for Medical Scientists and the NIH Director's Early Independence Award (DP5-OD029586). A.J.S. is supported by NIH grant F30-DK127699. A.J.S., M.A.R., and H.A.K. are supported by NIH grant T32-GM007347. A.N. is supported by Knut and Alice Wallenberg Foundation (KAW 2017.0436). A.P.R. is supported by NIH grants R01 HL148565 and R01 HL146500. B.L.E. is supported by Leducq Foundation. G.G. is supported by NIH grants R01 MH104964 and R01 MH123451, and Stanley Center for Psychiatric Research. K.C., Y.V.S., and P.W.F.W are supported by Million Veteran Program (MVP) grant numbers I01-BX003340 and I01-BX004821. K.P. is supported by grants from the NHLBI (5-T32HL007208-43). M.C.H. is supported by the American Heart Association (940166 and 979465). P.N. is supported by grants from the NHLBI (R01HL142711, R01HL127564, R01HL148050, R01HL151283, R01HL148565, R01HL135242, R01HL151152), National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125782), Fondation Leducq (TNE-18CVD04), and Massachusetts General Hospital (Paul and Phyllis Fireman Endowed Chair in Vascular Medicine). P.T.E. is supported by the National Institutes of Health (1RO1HL092577), the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and the European Union (MAESTRIA 965286). S.J. is supported by the Burroughs Wellcome Fund Career Award for Medical Scientists, Fondation Leducq (TNE-18CVD04), the Ludwig Center for Cancer Stem Cell Research at Stanford University, and the National Institutes of Health (DP2-HL157540). T.M.M. is supported by NIH grant T32-HL144446. V.G.S. is supported by NIH grants R01 DK103794 and R01 HL146500.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study was conducted under UK Biobank (UKB) application ID 7089 and 50834. Secondary use of the UKB data was approved by the Mass General Brigham Institutional Review Board (protocol 2021P002228). Secondary analysis of the TOPMed data was approved by the Mass General Brigham Institutional Review Board (protocol 2016P001308). The secondary analyses of Mass General Brigham Biobank data were approved by the Massachusetts General Hospital Institutional Review Board (protocol 2018P001236). The secondary analyses of BioVU data were approved by the Vanderbilt University Medical Center Institutional Review Board (IRB #201783).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
